The Irish Government has signed a major new agreement with pharmaceutical companies that promises quicker access to medicines and lower costs for patients across the country.
Under the new deal, the time it takes for new medicines to reach patients will be sharply reduced. At present, life-saving drugs often take more than 600 days to be approved and made available in Ireland. The agreement aims to cut this to 180 days, or six months. This means faster access to treatments for conditions such as cancer, heart disease and other serious illnesses.
A key part of the agreement involves the increased use of generic and biosimilar medicines. The Health Service Executive will prioritise these lower-cost medicines, which are considered equally safe and effective as branded versions. The savings generated will be reinvested to fund newer and more advanced treatments.
The deal also addresses inequality in access to medicines. Until now, patients with private health insurance often received new drugs sooner than those relying on the public system. The new agreement is designed to ensure equal and faster access for all patients, regardless of insurance status.
Key points
-
Agreement runs until the end of 2029
-
Focus on reducing medicine shortages
-
Faster access and lower costs for patients
Health Minister Jennifer Carroll MacNeill described the agreement as a historic step, saying it will bring real relief to thousands of patients who have been waiting too long for essential medicines.